The Dual Edema-Preventing Molecular Mechanism of the Crataegus Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions

Abstract

The hawthorn (Crataegus spp.) extract WS 1442 is used against mild forms of chronic heart failure. This disease is associated with endothelial barrier dysfunction and edema formation. We have recently shown that WS 1442 protects against this dysfunction by a dual mechanism: it both promotes endothelial barrier integrity by activation of a barrier-enhancing pathway (cortactin activation) and inhibits endothelial hyperpermeability by blocking a barrier disruptive pathway (calcium signaling). In this study, we aimed to identify the bioactive compounds responsible for these actions by using a bioactivity-guided fractionation approach. From the four fractions generated from WS 1442 by successive elution with water, 95 % ethanol, methanol, and 70 % acetone, only the water fraction was inactive, whereas the other three triggered a reduction of endothelial hyperpermeability. Analyses of intracellular calcium levels and cortactin phosphorylation were used as readouts to estimate the bioactivity of subfractions and isolated compounds. Interestingly, only the ethanolic fraction interfered with the calcium signaling, whereas only the methanolic fraction led to an activation of cortactin. Thus, the dual mode of action of WS 1442 could be clearly assigned to two distinct fractions. Although the identification of the calcium-active substance(s) was not successful, we could exclude an involvement of phenolic compounds. Cortactin activation, however, could be clearly attributed to oligomeric procyanidins with a distinct degree of polymerization. Taken together, our study provides the first approach to identify the active constituents of WS 1442 that address different cellular pathways leading to the inhibition of endothelial barrier dysfunction.

Key words

Crataegus spp. - Rosaceae - endothelial permeability - bioactivity-guided fractionation - oligomeric procyanidins - intracellular calcium levels - cortactin activation

^* These authors contributed equally to this work.

• References

• 1 Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002; 143: 910-915
• 2 Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008; (01) CD005312
• 3 Zapfe jr. G. Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine 2001; 8: 262-266
• 4 Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. BMC Complement Altern Med 2012; 12: 26
• 5 Idris-Khodja N, Auger C, Koch E, Schini-Kerth VB. Crataegus special extract WS 1442 prevents aging-related endothelial dysfunction. Phytomedicine 2012; 19: 699-706
• 6 Schmidt U, Kuhn U, Ploch M, Hubner WD. Efficacy of the Hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994; 1: 17-24
• 7 Eggeling T, Regitz-Zagrosek V, Zimmermann A, Burkart M. Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure – a pooled analysis of clinical trials. Phytomedicine 2011; 18: 1214-1219
• 8 Härtel S, Kutzner C, Westphal E, Limberger M, Burkart M, Ebner-Priemer U, Kohl-Bareis M, Bös K. Effects of endurance exercise training and Crataegus extract WS 1442 in patients with heart failure with preserved ejection fraction – a randomized controlled trial. Sports 2014; 2: 59-75
• 9 Bubik MF, Willer EA, Bihari P, Jürgenliemk G, Ammer H, Krombach F, Zahler S, Vollmar AM, Fürst R. A novel approach to prevent endothelial hyperpermeability: the Crataegus extract WS 1442 targets the cAMP/Rap1 pathway. J Mol Cell Cardiol 2012; 52: 196-205
• 10 Willer EA, Malli R, Bondarenko AI, Zahler S, Vollmar AM, Graier WF, Fürst R. The vascular barrier-protecting hawthorn extract WS 1442 raises endothelial calcium levels by inhibition of SERCA and activation of the IP3 pathway. J Mol Cell Cardiol 2012; 53: 567-577
• 11 Chatterjee SS, Koch E, Jaggy H, Krzeminski T. In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms. Arzneimittelforschung 1997; 47: 821-825
• 12 Horan KL, Adamski SW, Ayele W, Langone JJ, Grega GJ. Evidence that prolonged histamine suffusions produce transient increases in vascular permeability subsequent to the formation of venular macromolecular leakage sites. Proof of the Majno-Palade hypothesis. Am J Pathol 1986; 123: 570-576
• 13 Robert AM, Tixier JM, Robert L, Legeais JM, Renard G. Effect of procyanidolic oligomers on the permeability of the blood-brain barrier. Pathol Biol (Paris) 2001; 49: 298-304
• 14 Fan Y, Wu DZ, Gong YQ, Zhou JY, Hu ZB. Effects of calycosin on the impairment of barrier function induced by hypoxia in human umbilical vein endothelial cells. Eur J Pharmacol 2003; 481: 33-40
• 15 Potterat O, Hamburger M. Combined use of extract libraries and HPLC-based activity profiling for lead discovery: potential, challenges, and practical considerations. Planta Med 2014; 80: 1171-1181
• 16 Hellenbrand N, Sendker J, Lechtenberg M, Petereit F, Hensel A. Isolation and quantification of oligomeric and polymeric procyanidins in leaves and flowers of Hawthorn (Crataegus spp.). Fitoterapia 2015; 104: 14-22
• 17 Blazso G, Gabor M, Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 1997; 52: 380-382
• 18 Dongmo AB, Kamanyi A, Anchang MS, Chungag-Anye Nkeh B, Njamen D, Nguelefack TB, Nole T, Wagner H. Anti-inflammatory and analgesic properties of the stem bark extracts of Erythrophleum suaveolens (Caesalpiniaceae), Guillemin & Perrottet. J Ethnopharmacol 2001; 77: 137-141
• 19 Holt RR, Lazarus SA, Sullards MC, Zhu QY, Schramm DD, Hammerstone JF, Fraga CG, Schmitz HH, Keen CL. Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am J Clin Nutr 2002; 76: 798-804
• 20 Sano A, Yamakoshi J, Tokutake S, Tobe K, Kubota Y, Kikuchi M. Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. Biosci Biotechnol Biochem 2003; 67: 1140-1143
• 21 Tsang C, Auger C, Mullen W, Bornet A, Rouanet JM, Crozier A, Teissedre PL. The absorption, metabolism and excretion of flavan-3-ols and procyanidins following the ingestion of a grape seed extract by rats. Br J Nutr 2005; 94: 170-181
• 22 Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690
• 23 Zumdick S, Petereit F, Luftmann H, Hensel A. Preparative isolation of oligomeric procyanidins from Hawthorn (Crataegus spp.). Pharmazie 2009; 64: 286-288